Company Milestones

History of Wren Laboratories

JUL 2014
L
JUL 2014

Laboratory establishment, Branford, Connecticut.

OCT 2014
L
OCT 2014

Clinical laboratory certification in Connecticut, CLIA license for the NETest.

MAY 2018
L
MAY 2018

California Department of Health Permit - NETest.

AUG 2018
L
AUG 2018

New York State Department of Health Permit – NETest.

OCT 2018
L
OCT 2018

Development of the PPQ – PRRT Predictive Quotient.

NOV 2019
L
NOV 2019

Set-up of NETesting at Sarah Cannon, UK.

AUG 2019
L
AUG 2019

FDA-EUA for nasopharyngeal swab SARS-CoV-2 diagnosis.

OCT 2020
L
OCT 2020

FDA-EUA for COVID-19 PCR saliva testing.

JAN 2021
L
JAN 2021

Development of an at-home saliva collection kit.

DEC 2022
L
DEC 2022

CAP certification.

MAR 2023
L
MAR 2023

Development of the PROSTest – a molecular genomic assay for prostate cancers.

OCT 2023
L
OCT 2023

Completed PROSTest clinical validation study

DEC 2023
L
DEC 2023

Completed a screening study on high-risk men of African descent for prostate cancer.

MAR 2024
L
MAR 2024

Completed the evaluation of the PROSTest as a marker for minimal residual disease (MRD).

APR 2024
L
APR 2024

Completed the publication of the first article about PROSTest.

MAY 2024
L
MAY 2024

PROSTest approved by CLIA and submitted to NYSDOH.

JUN 2024
L
JUN 2024

Finalizing two clinical studies evaluating the PROSTest as a monitor for 177Lu-PSMA (Pluvicto) radioligand therapy (RLT).

About Wren 

From History to Innovation: Pioneering mRNA Science to Revolutionize Medicine for Patients

Pioneering Liquid Biopsy

Inspired by Sir Christopher Wren, one of the first to draw blood from human veins, two decades ago, Wren has foreseen whole blood as alternative option to  invasive tumor biopsy in the development of IVDs for cancer patient.

The Power of mRNA

While DNA and protein diagnostics are common, we specialize in mRNA. Positioned between DNA and proteins, mRNA in whole blood provides a real-time picture of tumor activity. Our novel preservative ensures stable and reliable testing.

Our Mission at Wren

We deliver innovative machine learning, liquid biopsy-RNA-based in-vitro diagnostics, for the detection of minimal residual disease and prediction  of cancer prognosis and response to therapeutics.  

Year Wren Laboratories was founded

Number of Patents

Number of genes analyzed by the NETest

Number of genes analyzed by the PROSTest

%

Clinical accuracy for PROSTest (vs. 48% for PSA)

Advancing Cancer Care

Precision Oncology Through mRNA Liquid Biopsy

For 40 years, complex tumor resections aimed to improve survival rates, but often relied on optimism. Recognizing the need for more sensitive detection, Wren’s founders began exploring liquid biopsy in 2004 to identify residual cancer cells through genetic markers in the bloodstream. Wren’s research now focuses on genetic signatures from tumors in blood and saliva, enabling early cancer detection and monitoring minimal residual disease (MRD). Today, Wren’s portfolio includes tests for various cancers such as prostate, neuroendocrine, myeloma, colon, and lung. With a simple blood test, Wren is making non-invasive mRNA liquid biopsy a reality.

Dr. Irvin Modlin

Contributions to Cancer Diagnosis and Gastroenterological Research

Dr. Irvin Modlin is currently Emeritus Professor of Gastroenterological Surgery at Yale University, School of Medicine and formerly director of the GI Pathobiology Research Group. He has authored ~ 600 peer-reviewed scientific and clinical papers and written ~16 books on diverse subjects including acid peptic disease, pancreatic maladies, laparoscopic surgery, endoscopy, the evolution of therapy, the history of medicine, the medical evolution of cities, and Dutch art. 

Dr. Modlin’s current clinical interests are in the introduction of molecular genomics to the blood-based diagnosis of different forms of cancer (prostate, colon, neuroendocrine). His team has introduced finger-prick-based molecular genomic assessment of cancer disease status and therapy monitoring. The identification of specific circulating gene signatures of cancer allows for its detection prior to recognition by CT/MRI and can identify progression and metastatic disease prior to anatomical and functional imaging.

Biography >